Using AI and PET/MRI to predict breast cancer response
Part of Cancer clinical trials.
This trial uses a special PET/MRI scan combined with artificial intelligence to see if it can predict whether HER2-positive breast cancer will completely disappear after treatment given before surgery. The goal is to learn who might avoid surgery or get a more tailored approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and at least 18 years old.
- Your breast cancer is HER2-positive (a specific type of breast cancer that may respond to targeted therapy).
- You have decided to receive chemotherapy or other treatment before surgery (neoadjuvant therapy).
- You do not have another active cancer or a history of cancer in the last 5 years.
- You are able to have an MRI scan (no metal implants, pacemaker, or severe kidney problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well CT and PET scans can predict if a certain type of breast cancer will respond to a targeted treatment. It focuses on women who had a biopsy of the liver, lung, or chest lining after the cancer spread.
This trial uses AI to analyze your pre-treatment MRI and predict how well your tumor will respond to chemotherapy before surgery. It is for people with HR+/HER2- breast cancer who need chemo before their operation.
This early-phase study looks at how well PET/MRI scans can monitor treatment response in people with HER2-positive breast cancer before surgery. You may be asked to undergo specific scans during “neoadjuvant” therapy (treatment given before the main operation).
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
This study uses special PET/MRI scans to see how well breast cancer treatments are working. It aims to find better ways to monitor your cancer and guide your care.
This trial uses an artificial intelligence model to predict how well breast cancer responds to neoadjuvant therapy (treatment before surgery). It aims to improve treatment planning by analyzing MRI scans taken before and after therapy.
Hear when a new HER2 Positive Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.